Autres langues Perspective Therapeutics, Inc.

Actions

CATX

US46489V3024

Recherche biotechnologique et médicale

Marché Fermé - NYSE Autres places de cotation 22:00:00 17/06/2026			Varia. 5j.	Varia. 1 janv.
2,980 ^USD	+1,71 %		+1,02 %	+8,36 %

03/06	Perspective Therapeutics administre la première dose à un patient atteint de méningiome dans le cadre d'une étude de phase 1/2a	MT
03/06	Perspective Therapeutics administre la première dose de [212Pb]VMT-α-NET à un patient atteint de méningiome dans le cadre d'une étude de phase 1/2a	CI

Autres langues

03/06	Perspective Therapeutics Doses First Meningioma Patient in Phase 1/2a Study Cohort
03/06	Perspective Therapeutics Expands Therapeutic Focus Areas; First Patient Dosed with [212Pb]VMT-α-NET in the Meningioma Cohort of a Phase 1/2a Study
03/06	Perspective Therapeutics Doses First Patient with [212Pb]Vmt-?-Net in Meningioma Cohort of Phase 1/2A Study
21/05	Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma
18/05	Perspective Therapeutics, Inc. Announces First Patients Dosed In New Cohorts Of Ongoing Phase 1/2a Studies
18/05	Perspective Therapeutics Doses First Patients for New Cohorts of Two Phase 1/2a Studies in Tumors
18/05	Perspective Therapeutics Announces First Patients Dosed in New Cohorts of Two Ongoing Phase 1/2a Studies
11/05	Perspective Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
11/05	Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2026 Results
24/04	Perspective Therapeutics to Provide Several Upcoming Corporate Updates
20/04	Perspective Therapeutics Provides Updated Interim Results From Phase 1/2a Cancer Trial
20/04	Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in Its Ongoing Phase 1/2a Clinical Trial at the 2026 AACR Annual Meeting
20/04	Perspective Therapeutics Inc Presents Updated Interim Data of [212Pb]VMT-a-NET in Ongoing Phase 1/2A Clinical Trial
02/04	Perspective Therapeutics to Participate in Upcoming Investor Conferences
23/03	Perspective Therapeutics, Inc.(NYSEAM:CATX) added to S&P Biotechnology Select Industry Index
17/03	Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the AACR Annual Meeting 2026
16/03	Perspective Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025
16/03	Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2025 Results
17/02	Perspective Therapeutics to Provide Business Highlights and Report Full Year 2025 Financial Results
02/02	Perspective Therapeutics Announces Pricing of $175 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
12/01	Perspective Therapeutics Provides Business Updates and Strategic Priorities Ahead of Presentation at 44th Annual J.P. Morgan Healthcare Conference
12/01	Perspective Therapeutics, Inc. Provides Clinical Updates
09/01	Perspective Therapeutics, Inc. Announces Updated Interim Results from Its Ongoing Phase 1/2A Clinical Trial
09/01	Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial at the 2026 ASCO Gastrointestinal Cancers Symposium
18/12	Perspective Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference